As soon as-yearly jab for HIV safety passes first trial hurdle
Michelle Roberts Digital well being editor, BBC Information Getty Photos An annual injection designed to protect in opposition to Human Immunodeficiency Virus (HIV) has accomplished an necessary early security trial, researchers report in The Lancet medical journal. Lenacapavir stops the virus from replicating inside cells. If future trials go properly – now it has handed…